Intravenous zoledronic acid for the treatment of osteoporosis

Current Osteoporosis Reports

Volumn 6, Issue 1, 2008, Pages 17-23

  Lewiecki, E Michael ^a  

^a NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; STRONTIUM RANELATE; VITAMIN D; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIAGNOSTIC ERROR; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; FRAGILITY FRACTURE; HEART ATRIUM FIBRILLATION; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; KIDNEY DYSFUNCTION; KINESIOTHERAPY; MUSCLE DISEASE; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SELECTION; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SIDE EFFECT; TREATMENT DURATION; DOSE RESPONSE; FRACTURE; INTRAVENOUS DRUG ADMINISTRATION; RISK FACTOR;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FRACTURES, BONE; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; OSTEOPOROSIS; RISK FACTORS;

EID: 44849126108     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-008-0004-x     Document Type: Review

References (42)

1. National Osteoporosis Foundation: Fast Facts on Osteoporosis. http://www.nof.org/osteoporosis/diseasefacts.htm. Accessed July 27, 2007.
2. ReginsteA JY, Burlet N: Osteoporosis: a still increasing prevalence. Bone 2006, 38:S4-S9.
3. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy: Osteoporosis prevention, diagnosis, and therapy. JAMA 2001, 285:785-795.
4. Kanis JA, Johnell O, Oden A, et al.: Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001, 12:989-995.
5. Arden NK, Nevitt MC, Lane NE, et al.: Study of Osteoporotic Fractures Research Group. Osteoarthritis and risk of falls, rates of bone loss, and osteoporotic fractures. Arthritis Rheum 1999, 42:1378-1385.
6. Burge R, Dawson-Hughes B, Solomon DH, et al.: Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007, 22:465-475.
7. Brenneman SK, Barrett-Connor E, Sajjan S, et al.: Impact of recent fracture on health-related quality of life in postmenopausal women. J Bone Miner Res 2006, 21:809-816.
8. Kanis JA, Johnell OA: Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 2005, 16:229-238.
9. Gabriel SE, Tosteson AN, Leibson CL, et al.: Direct medical costs attributable to osteoporotic fractures. Osteoporos Int 2002, 13:323-330.
10. Gehlbach SH, Avrunin JS, Puleo E, Spaetyh R: Fracture risk and antiresorptive medication use in older women in the USA. Osteoporos Int 2007, 18:805-810.
11. Haussler B, Gothe H, Gold D, et al.: Epidemiology, treatment and costs of osteoporosis in Germany - the BoneEVA Study. Osteoporos Int 2007, 18:77-84.
12. Vestergaard P, Rejnmark L, Mosekilde L: Osteoporosis is markedly underdiagnosed: A nationwide study from Denmark. Osteoporos Int 2005, 16:134-141.
13. Kim N, Rowe BH, Raymond G, et al.: Underreporting of vertebral fractures on routine chest radiography. AJR Am J Roentgenol 2004, 182:297-300.
14. Morris CA, Carrino JA, Lang P, et al.: Incidental vertebral fractures on chest radiographs. Recognition, documentation, and treatment. J Gen Intern Med 2006, 21:352-356.
15. Majumdar SR, Kim N, Colman I, et al.: Incidental vertebral fractures discovered with chest radiography in the emergency department: prevalence, recognition, and osteoporosis management in a cohort of elderly patents. Arch Intern Med 2005, 165:905-909.
16. Lewiecki EM: Review of guidelines for bone mineral density testing and treatment of osteoporosis. Curr Osteoporos Rep 2005, 3:75-83.
17. Black DM, Delmas PD, Eastell R, et al.: For the HORIZON Pivotal Fracture Trial: Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356: 1809-1822.
18. Black DM, Thompson DE, Bauer DC, et al.: Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000, 85:4118-4124.
19. Chesnut IC, Skag A, Christiansen C, et al.: Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004, 19:1241-1249.
20. Cummings SR, Black DM, Thompson DE, et al.: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 1998, 280:2077-2082.
21. Harris ST, Watts NB, Genant HK, et al.: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999, 282:1344-1352.
22. McClung MR, Geusens P, Miller PD, et al.: Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001, 344:333-340.
23. Reginster J, Minne HW, Sorensen OH, et al.: Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000, 11:83-91.
24. Cramer JA, Amonkar MM, Hebborn A, Altman R: Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005, 21:1453-1460.
25. Lo JC, Pressman AR, Omar MA, Ettinger B: Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 2006, 17:922-928.
26. Weiss TW, von Allmen H, Henderson SC, et al.: Persistency rates across weekly and monthly bisphosphonates: Results from the IMS Health Longitudinal Prescription Database [poster P8.13]. Presented at the National Osteoporosis Foundation 7th International Symposium on Osteoporosis: Translating Research into Clinical Practice. Washington, DC; April 18-22, 2007.
27. Caro JJ, Ishak KJ, Huybrechts KF, et al.: The impact of compliance with osteoporosis therapy on fracture rates in clinical practice. Osteoporos Int 2004, 15:1003-1008.
28. Huybrechts KF, Ishak KJ, Caro JJ: Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006, 38:922-928.
29. Siris ES, Harris ST, Rosen CJ, et al.: Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006, 81:1013-1022.
30. Recker RR, Gallagher R, MacCosbe PE: Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005, 80:856-861.
31. Cooper A, Drake J, Brankin E, the PERSIST Investigators: Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: Results from the PERSIST study. Int J Clin Pract 2006, 60: 896-905.
32. Lyles K, Colon-Emeric C, Magaziner J, et al.: Zoledronic acid reduces clinical fractures and mortality after hip fracture. N Engl J Med 2007, 357:1799-1809.
33. McClung M, Recker R, Miller P, et al.: Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 2007, 41:122-128.
34. Gertz BJ, Holland SD, Kline WF, et al.: Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 1995, 58:288-298.
35. De Groen PC, Lubbe DF, Hirsch LJ, et al.: Esophagitis associated with use of alendronate. N Engl J Med 1996, 335:1016-1021.
36. Downey TW, Foltz SH, Boccuzzi SJ, et al.: Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J 2006, 99:570-575.
37. Aclasta Package Insert. Basel, Switzerland: Novartis Pharmaceuticals; 2007.
38. Khosla S, Burr D, Cauley J, et al.: Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007, 22:1479-1491.
39. Woo SB, Hellstein JW, Kalmar JR: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006, 144:753-756.
40. Sambrook P, Over I, Goss A, New Zealand Bone and Mineral Society, Osteoporosis Australia, Medical Oncology Group of Australia, and the Australian Dental Association: Bisphosphonates and osteonecrosis of the jaw. Clinical practice position. Aust Fam Physician 2006, 35: 801-803.
41. Felsenberg D, Hoffmeister B, Amling M, et al.: Kiefernekrosen nach hoch dosierter bisphosphonattherapie. Dtsch Arztebl 2006, 103:3078-3081.
42. National Osteoporosis Foundation: Osteoporosis Clinical Practice Guideline. http://www.nof.org/professionals/clinical.htm. Accessed July 27, 2007.